Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 38.7% in January

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 58,591 shares, a decrease of 38.7% from the December 31st total of 95,551 shares. Approximately 2.5% of the shares of the stock are sold short. Based on an average daily volume of 352,079 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 352,079 shares, the short-interest ratio is presently 0.2 days. Approximately 2.5% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

VRAX has been the topic of a number of research reports. Zacks Research raised Virax Biolabs Group to a “hold” rating in a research note on Tuesday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $1.00 price target (down from $3.00) on shares of Virax Biolabs Group in a research report on Friday, January 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a report on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $1.00.

Virax Biolabs Group Stock Down 1.7%

Shares of Virax Biolabs Group stock opened at $0.29 on Friday. Virax Biolabs Group has a 12-month low of $0.26 and a 12-month high of $2.29. The stock’s fifty day moving average is $0.38 and its 200-day moving average is $0.57.

Virax Biolabs Group (NASDAQ:VRAX) last issued its quarterly earnings results on Tuesday, December 2nd. The company reported ($0.27) earnings per share for the quarter. The company had revenue of $0.00 million during the quarter.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.